Uneingeschränkter Zugang

Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor

Jiyang Tang

Jiyang Tang

Department of Thoracic Surgery, The Third Affiliated Hospital of ZunYi Medical University (The First People's Hospital of ZunYi)Zunyi, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Tang, Jiyang
, 
Dejun Shu

Dejun Shu

Department of Thoracic Surgery, The Third Affiliated Hospital of ZunYi Medical University (The First People's Hospital of ZunYi)Zunyi, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Shu, Dejun
, 
Zhimin Fang

Zhimin Fang

Department of Thoracic Surgery, The Third Affiliated Hospital of ZunYi Medical University (The First People's Hospital of ZunYi)Zunyi, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Fang, Zhimin
 und 
Gaolan Yang

Gaolan Yang

Department of Thoracic Surgery, The Third Affiliated Hospital of ZunYi Medical University (The First People's Hospital of ZunYi)Zunyi, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Yang, Gaolan
  
04. Sept. 2023
Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
COVER HERUNTERLADEN
Artikel-Kategorie: Research Article
Online veröffentlicht: 04. Sept. 2023
Seitenbereich: 325 - 336
Eingereicht: 21. Dez. 2022
Akzeptiert: 21. Juni 2023
DOI: https://doi.org/10.2478/raon-2023-0033
Schlüsselwörter
© 2023 Jiyang Tang et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

PROM2 is overexpressed in non-small cell lung cancer (NSCLC). (A) Expression level of PROM2 in normal group and tumor. (B–D) GEO microarray data GSE32863 was analyzed by LIMMA package using R language to compare the expression of differential genes (DEGs) in lung cancer tissues and adjacent normal tissues. The data were corrected and analyzed by PCA (B), and the volcano map (C) and heat map (D) were drawn. (E–F) To analyze the expression level of PROM2 in non-small cell lung cancer (TCGA-LUAD and TCGA-LUSC) using online platform GEPIA based on TCGA database. (G) Kaplan-Meier plotter was used to analyze the effect of PROM2 expression on prognosis. (H) Representative immunohistochemical picture of PROM2 in NSCLC. (I) PROM2 protein level in NSCLC by Western blotting. (J) The protein expression of PROM2 in human normal lung epithelial cells (BEAS-2B) and lung cancer cells (NCI-H1650, A549, NCI-H1299, PC-9) was detected by western blotting.*P < 0.05, **P < 0.01, ***P < 0.001 compared with normal group/BEAS-2B group
PROM2 is overexpressed in non-small cell lung cancer (NSCLC). (A) Expression level of PROM2 in normal group and tumor. (B–D) GEO microarray data GSE32863 was analyzed by LIMMA package using R language to compare the expression of differential genes (DEGs) in lung cancer tissues and adjacent normal tissues. The data were corrected and analyzed by PCA (B), and the volcano map (C) and heat map (D) were drawn. (E–F) To analyze the expression level of PROM2 in non-small cell lung cancer (TCGA-LUAD and TCGA-LUSC) using online platform GEPIA based on TCGA database. (G) Kaplan-Meier plotter was used to analyze the effect of PROM2 expression on prognosis. (H) Representative immunohistochemical picture of PROM2 in NSCLC. (I) PROM2 protein level in NSCLC by Western blotting. (J) The protein expression of PROM2 in human normal lung epithelial cells (BEAS-2B) and lung cancer cells (NCI-H1650, A549, NCI-H1299, PC-9) was detected by western blotting.*P < 0.05, **P < 0.01, ***P < 0.001 compared with normal group/BEAS-2B group

FIGURE 2.

PROM2 promotes the proliferation of lung cancer cells. (A–D) PROM2 was overexpressed or knocked down in A549 and PC-9 cells. The protein level of PROM2 was detected by western blotting (A), cell viability was detected by CCK8 (B), cell proliferation was detected by clonal formation (C). Transwell was used to detect cell migration and cell invasion (D).*P < 0.05, **P < 0.01, ***P < 0.001 compared with siNC; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with vector
PROM2 promotes the proliferation of lung cancer cells. (A–D) PROM2 was overexpressed or knocked down in A549 and PC-9 cells. The protein level of PROM2 was detected by western blotting (A), cell viability was detected by CCK8 (B), cell proliferation was detected by clonal formation (C). Transwell was used to detect cell migration and cell invasion (D).*P < 0.05, **P < 0.01, ***P < 0.001 compared with siNC; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with vector

FIGURE 3.

PROM2 attenuates the sensitivity of lung cancer cells to cisplatin. (A) Cell viability was detected by CCK8. (B) The expression level of PROM2 in different groups of cells was detected by western blotting. (C–F) PROM2 was knocked down or overexpressed in A549/DDP and PC-9/DDP, and then the protein level of PROM2 was detected by western blotting, cell viability was detected by CCK8 (D), cell proliferation was detected by clone formation (E), and cell apoptosis was detected by flow cytometry (F).**P < 0.01, ***P < 0.001 compared with A549 group; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with vector
PROM2 attenuates the sensitivity of lung cancer cells to cisplatin. (A) Cell viability was detected by CCK8. (B) The expression level of PROM2 in different groups of cells was detected by western blotting. (C–F) PROM2 was knocked down or overexpressed in A549/DDP and PC-9/DDP, and then the protein level of PROM2 was detected by western blotting, cell viability was detected by CCK8 (D), cell proliferation was detected by clone formation (E), and cell apoptosis was detected by flow cytometry (F).**P < 0.01, ***P < 0.001 compared with A549 group; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with vector

FIGURE 4.

PROM2 enhances cisplatin resistance in lung cancer cells in vivo. BALB/c nude mice were subcutaneously injected with PROM2 knockdown stable A549/DDP cells. One week later, cisplatin (4 mg/kg) was injected into the peritoneum every 3 days. After 30 days, the cells were removed and the volume and weight were measured. (A) The volume and weight of tumors in different groups were detected. (B) The protein levels of PROM2 in different groups were detected by Western blotting.***P < 0.001 compared with shNC group; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with cisplatin+shNC
PROM2 enhances cisplatin resistance in lung cancer cells in vivo. BALB/c nude mice were subcutaneously injected with PROM2 knockdown stable A549/DDP cells. One week later, cisplatin (4 mg/kg) was injected into the peritoneum every 3 days. After 30 days, the cells were removed and the volume and weight were measured. (A) The volume and weight of tumors in different groups were detected. (B) The protein levels of PROM2 in different groups were detected by Western blotting.***P < 0.001 compared with shNC group; $P < 0.05, $$P < 0.01, $$$P < 0.001 compared with cisplatin+shNC

FIGURE 5.

Up-regulation of PROM2 induced by CTCF. (A) TIMER 2.0 data analysis revealed that CTCF was overexpressed in lung cancer. (B) There was a positive correlation between CTCF and PROM2 in LUAD and LUSC data analyzed by GEPIA platform. (C) Protein levels of PROM2 and CTCF were detected by western blotting. (D) The expression level of PROM2 was detected by ChIP-PCR.**P < 0.01, ***P < 0.001 compared with vector group; $$$P < 0.001 compared with siNC
Up-regulation of PROM2 induced by CTCF. (A) TIMER 2.0 data analysis revealed that CTCF was overexpressed in lung cancer. (B) There was a positive correlation between CTCF and PROM2 in LUAD and LUSC data analyzed by GEPIA platform. (C) Protein levels of PROM2 and CTCF were detected by western blotting. (D) The expression level of PROM2 was detected by ChIP-PCR.**P < 0.01, ***P < 0.001 compared with vector group; $$$P < 0.001 compared with siNC

FIGURE 6.

CTCF knockdown increased the sensitivity of lung cancer cells to cisplatin by down-regulating PROM2. (A–D) After knockdown of CTCF and/or overexpression of PROM2 in A549/DDP, the protein levels of CTCF and PROM2 were detected by western blotting (A), cell viability was detected by CCK8 (B), cell proliferation was detected by clone formation (C), and cell apoptosis was detected by flow cytometry (D).*P < 0.05, ***P < 0.001 compared with siNC+vector; $P < 0.05, $$$P < 0.001 compared with siCTCF#1+vector
CTCF knockdown increased the sensitivity of lung cancer cells to cisplatin by down-regulating PROM2. (A–D) After knockdown of CTCF and/or overexpression of PROM2 in A549/DDP, the protein levels of CTCF and PROM2 were detected by western blotting (A), cell viability was detected by CCK8 (B), cell proliferation was detected by clone formation (C), and cell apoptosis was detected by flow cytometry (D).*P < 0.05, ***P < 0.001 compared with siNC+vector; $P < 0.05, $$$P < 0.001 compared with siCTCF#1+vector

Data of ENCODE ChIP-seq

TFs Signal peak ENCODE ID
CTCF 114.601 ENCFF797HKW
REST 94.922 ENCFF044DWW
MAFK 71.984 ENCFF757FDG
TEAD4 34.118 ENCFF186WSI

The patient characteristics had no statistical significance

Clinicopathological factor Number of cases PROM2 expression P value
High Low
Total Cases 35 19 16
Gender 0.606
  Male 22 13 9
  Female 13 6 7
Age 0.814
  < 60 17 9 8
  ≥ 60 18 10 8
Histological type 0.189
  LSCC 12 9 3
  LAD 15 7 8
  LCLC 8 3 5
Pathological grading 0.002
  I 15 3 12
  II 11 8 3
  III 9 8 1
TNM stage 0.006
  I 13 3 10
  II 12 7 5
  III 10 9 1
Smoking history 0.3320
  yes 24 13 11
  no 11 6 5
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Medizin, Klinische Medizin, Allgemeinmedizin, Innere Medizin, Hämatologie, Onkologie, Radiologie
Zeitschrift RSS Feed